Hale David F - Feb 23, 2024 Form 4 Insider Report for Oncternal Therapeutics, Inc. (ONCT)

Role
Director
Signature
/s/Chase C. Leavitt, Attorney-in-fact
Stock symbol
ONCT
Transactions as of
Feb 23, 2024
Transactions value $
$8,859
Form type
4
Date filed
2/27/2024, 05:03 PM
Previous filing
Jan 5, 2024
Next filing
Jun 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ONCT Common Stock Purchase $6.45K +714 $9.04 714 Feb 23, 2024 Direct F1
transaction ONCT Common Stock Purchase $2.4K +266 +0.9% $9.04 29.7K Feb 23, 2024 By Hale BioPharma Ventures, LLC F1
holding ONCT Common Stock 917 Feb 23, 2024 By Hale Trading Company
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock were acquired directly from another director of the Issuer, Robert James Wills, in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024.

Remarks:

The number of shares of common stock in this form have been adjusted to reflect the Issuer's 1-for-20 reverse stock split effective as of January 8, 2024.